Literature DB >> 33671293

Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africa-Ethiopia, Kenya, Rwanda, and Tanzania.

Abbie Barry1, Sten Olsson1, Christabel Khaemba2, Joseph Kabatende3, Tigist Dires4, Adam Fimbo5, Omary Minzi6, Emile Bienvenu7, Eyasu Makonnen8,9, Appolinary Kamuhabwa6, Margaret Oluka10, Anastasia Guantai10, Eugène van Puijenbroek11, Ulf Bergman1, Alex Nkayamba5, Michael Mugisha7, Parthasarathi Gurumurthy12, Eleni Aklillu1.   

Abstract

Monitoring the safety of medicines used in public health programs (PHPs), including the neglected tropical diseases (NTD) program, is a WHO recommendation, and requires a well-established and robust pharmacovigilance system. The objective of this study was to assess the pharmacovigilance systems within the NTD programs in Ethiopia, Kenya, Rwanda, and Tanzania. The East African Community Harmonized Pharmacovigilance Indicators tool for PHPs was used to interview the staff of the national NTD programs. Data on four components, (i) systems, structures, and stakeholder coordination; (ii) data management and signal generation; (iii) risk assessment and evaluation; and (iv) risk management and communication, were collected and analyzed. The NTD programs in the four countries had a strategic master plan, with pharmacovigilance components and mechanisms to disseminate pharmacovigilance information. However, zero individual case safety reports were received in the last 12 months (2017/2018). There was either limited or no collaboration between the NTD programs and their respective national pharmacovigilance centers. None of the NTD programs had a specific budget for pharmacovigilance. The NTD program in all four countries had some safety monitoring elements. However, key elements, such as the reporting of adverse events, collaboration with national pharmacovigilance centers, and budget for pharmacovigilance activity, were limited/missing.

Entities:  

Keywords:  East Africa; Neglected Tropical Diseases Program; medicine safety; pharmacovigilance; public health program

Mesh:

Year:  2021        PMID: 33671293      PMCID: PMC7922898          DOI: 10.3390/ijerph18041941

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


  17 in total

1.  489 Global programme to eliminate lymphatic filariasis: progress report, 2014.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2015-09-18

2.  Safe mass drug administration for neglected tropical diseases.

Authors:  Dziedzom K de Souza; Thomas P C Dorlo
Journal:  Lancet Glob Health       Date:  2018-10       Impact factor: 26.763

3.  The global burden of neglected tropical diseases.

Authors:  A Fenwick
Journal:  Public Health       Date:  2012-02-09       Impact factor: 2.427

Review 4.  The contribution of mass drug administration to global health: past, present and future.

Authors:  Joanne P Webster; David H Molyneux; Peter J Hotez; Alan Fenwick
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-05-12       Impact factor: 6.237

5.  Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease.

Authors:  K D Ramaiah; Eric A Ottesen
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

6.  Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.

Authors:  Abbie Barry; Sten Olsson; Omary Minzi; Emile Bienvenu; Eyasu Makonnen; Appolinary Kamuhabwa; Margaret Oluka; Anastasia Guantai; Ulf Bergman; Eugène van Puijenbroek; Parthasarathi Gurumurthy; Eleni Aklillu
Journal:  Drug Saf       Date:  2020-04       Impact factor: 5.606

7.  Prevalence and Correlates of Lymphatic Filariasis Infection and Its Morbidity Following Mass Ivermectin and Albendazole Administration in Mkinga District, North-Eastern Tanzania.

Authors:  Adam M Fimbo; Omary M S Minzi; Bruno P Mmbando; Abbie Barry; Alex F Nkayamba; Kissa W Mwamwitwa; Alpha Malishee; Misago D Seth; Williams H Makunde; Parthasarathi Gurumurthy; John P A Lusingu; Appolinary A R Kamuhabwa; Eleni Aklillu
Journal:  J Clin Med       Date:  2020-05-21       Impact factor: 4.241

8.  WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems.

Authors:  Shanthi N Pal; Chris Duncombe; Dennis Falzon; Sten Olsson
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

9.  MDA-Lymphatic Filariasis.

Authors:  Kazuyo Ichimori
Journal:  Trop Med Health       Date:  2014-06

10.  Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences.

Authors:  H Hilda Ampadu; Jarno Hoekman; Daniel Arhinful; Marilyn Amoama-Dapaah; Hubert G M Leufkens; Alex N O Dodoo
Journal:  Global Health       Date:  2018-11-16       Impact factor: 4.185

View more
  4 in total

1.  Safety culture and adverse event reporting in Ghanaian healthcare facilities: Implications for patient safety.

Authors:  Aaron Asibi Abuosi; Collins Atta Poku; Priscilla Y A Attafuah; Emmanuel Anongeba Anaba; Patience Aseweh Abor; Adelaide Setordji; Edward Nketiah-Amponsah
Journal:  PLoS One       Date:  2022-10-19       Impact factor: 3.752

2.  Safety and Tolerability of Ivermectin and Albendazole Mass Drug Administration in Lymphatic Filariasis Endemic Communities of Tanzania: A Cohort Event Monitoring Study.

Authors:  Adam M Fimbo; Omary Mashiku Minzi; Bruno P Mmbando; Parthasarathi Gurumurthy; Appolinary A R Kamuhabwa; Eleni Aklillu
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-12

Review 3.  A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators.

Authors:  Hamza Y Garashi; Douglas T Steinke; Ellen I Schafheutle
Journal:  Ther Innov Regul Sci       Date:  2022-06-03       Impact factor: 1.337

4.  An observational assessment of the safety of mass drug administration for trachoma in Ethiopian children.

Authors:  Allan M Ciciriello; David G Addiss; Tesfaye Teferi; Paul M Emerson; P J Hooper; Mohammed Seid; Girma Tadesse; Fikre Seife; Mohammed-Aman Jemal Sormolo; Fikreab Kebede; Genet Kiflu; Sheila K West; Menbere Alemu; Genevieve LaCon; Teshome Gebre
Journal:  Trans R Soc Trop Med Hyg       Date:  2022-10-02       Impact factor: 2.455

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.